Kiniksa Pharmaceuticals (Kiniksa Pharmaceuticals) Price-to-Operating-Cash-Flow : 61.95 (As of Apr. 30, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Kiniksa Pharmaceuticals Price-to-Operating-Cash-Flow?

As of today (2024-04-30), Kiniksa Pharmaceuticals's share price is $18.71. Kiniksa Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.30. Hence, Kiniksa Pharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is 61.95.

The historical rank and industry rank for Kiniksa Pharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:

KNSA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 19.72 Med: 57.25 Max: 222.39
Current: 101.23

During the past 8 years, Kiniksa Pharmaceuticals's highest Price-to-Operating-Cash-Flow Ratio was 222.39. The lowest was 19.72. And the median was 57.25.

KNSA's Price-to-Operating-Cash-Flow is ranked worse than
87.37% of 285 companies
in the Biotechnology industry
Industry Median: 24.83 vs KNSA: 101.23

Kiniksa Pharmaceuticals's Cash Flow from Operations per share for the three months ended in Mar. 2024 was $0.06. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.30.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Kiniksa Pharmaceuticals was -44.40% per year.

During the past 8 years, Kiniksa Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 12.40% per year. The lowest was -63.20% per year. And the median was -12.60% per year.

Kiniksa Pharmaceuticals Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Kiniksa Pharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiniksa Pharmaceuticals Price-to-Operating-Cash-Flow Chart

Kiniksa Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

182.68

94.81

Kiniksa Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															19.82	23.31	-	94.81	65.33

Competitive Comparison of Kiniksa Pharmaceuticals's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Kiniksa Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kiniksa Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiniksa Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Kiniksa Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.

Kiniksa Pharmaceuticals Price-to-Operating-Cash-Flow Calculation

Kiniksa Pharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	18.71	/	0.302
	=	61.95

Kiniksa Pharmaceuticals's Share Price of today is $18.71.
Kiniksa Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.30.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Kiniksa Pharmaceuticals Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Kiniksa Pharmaceuticals's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiniksa Pharmaceuticals (Kiniksa Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiniksa Pharmaceuticals Ltd (NAS:KNSA) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Church Street, Clarendon House, Hamilton, BMU, HM11

Website

https://www.kiniksa.com

Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404.

Executives

Michael R Megna	officer: Chief Accounting Officer	1050 HINGHAM STREET, ROCKLAND MA 02370
John Paolini	officer: Chief Medical Officer	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Barry D Quart	director	C/O INTRABIOTICS PHARMACEUTICALS INC, 1009 OAK HILL ROAD, SUITE 201, LAFAYETTE CA 94549
Felix Baker	director	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Eben Tessari	officer: Chief Business Officer	C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Arian Pano	officer: Chief Clinical Dev. Officer	C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Ross Moat	officer: Group VP & Rilonacept GM	C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Sanj K Patel	director, 10 percent owner, officer: Chairman & CEO	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Thomas W. Beetham	10 percent owner, officer: Chief Legal Officer	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Mark Ragosa	officer: Interim CFO	C/O KINIKSA PHARMACEUTICALS CORP., 100 HAYDEN AVENUE, LEXINGTON MA 02421